A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland by Aneta Bąk et al.
Bąk et al. Hereditary Cancer in Clinical Practice 2014, 12:10
http://www.hccpjournal.com/content/12/1/10RESEARCH Open AccessA risk of breast cancer in women - carriers of
constitutional CHEK2 gene mutations, originating
from the North - Central Poland
Aneta Bąk1*, Hanna Janiszewska1, Anna Junkiert-Czarnecka1, Marta Heise1, Maria Pilarska-Deltow1,
Ryszard Laskowski2, Magdalena Pasińska1 and Olga Haus1,3Abstract
Background: Germline mutations of the CHEK2 gene have been reported to be associated with breast cancer.
In this study, we analyzed the association of CHEK2 mutations with the risk of development of breast cancer in
women of North-Central Poland.
Methods: 420 women with breast cancer and 435 controls were tested for three protein truncating (IVS2 + 1G > A,
1100delC, del5395) and one missense (I157T) CHEK2 mutation. IVS2 + 1G > A and I157T mutations were identified by
RFLP-PCR, 1100delC variant was analyzed using an ASO-PCR and del5395 mutation by multiplex-PCR. The statistical
tests: the odds ratio (OR) and Fisher’s exact test were used.
Results: In 33 out of 420 (7.9%) women consecutively diagnosed with breast cancer, we detected one of four analyzed
CHEK2 mutations: I157T, 1100delC, IVS2 + 1G > A or del5395. Together they were not associated with the increased risk
of breast cancer (North-Central control group: OR = 1.6, p = 0.124; the general Polish population: OR = 1.4, p = 0.109).
This association was only seen for IVS2 + 1G > A mutation (OR = 3.0; p = 0.039). One of the three truncating CHEK2
mutations (IVS2 + 1G > A, 1100delC, del5395) was present in 9 of 420 women diagnosed with breast cancer (2.1%) and
in 4 of 121 women (3.3%) with a history of breast cancer in a first- and/or second- degree relatives. Together they were
associated with the increased risk of disease in these groups, compared to the general Polish population (OR = 2.1,
p = 0.053 and OR = 3.2; p = 0.044, respectively). I157T mutation was detected in 25 of 420 women diagnosed with
breast cancer (6.0%) and in 8 of 121 women (6.6%) with a history of breast cancer in first- and/or second- degree
relatives. The prevalance of I157T mutation was 4.1% (18/435) in North-Central control group and 4.8% (265/5.496)
in the general Polish population. However it was not associated with an increased risk of breast cancer.
Conclusion: Obtained results suggest that CHEK2 mutations could potentially contribute to the susceptibility to breast
cancer. The germline mutations of CHEK2, especially the truncating ones confer low-penetrance breast cancer predis-
position that contribute significantly to familial clustering of breast cancer at the population level.
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The genetic basis of breast cancer (BC) is very complex and
it is suggested that many various genes, especially tumor
suppressors could play role in disease development [1].
The CHEK2 tumor suppressor gene belongs to the
group of genes, which by regulating cell division protect* Correspondence: aneta.bak@cm.umk.pl
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unless otherwise stated.the cells against too rapid, uncontrolled growth. In re-
sponse to DNA damage Checkpoint kinase 2 (CHEK2)
is activated on ATM-dependent pathway and then phos-
phorylates several substrates, such as p53, BRCA1 protein,
CDC25A and CDC25C, involved in the cell cycle check-
point control, through coordination of DNA repair, cell
cycle progression and apoptosis [2].
Constitutional mutations of CHEK2 predispose to many
types of common cancers, e.g. breast cancer [3-5]. In
the general Polish population the most common CHEK2. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ture protein-truncating mutations: IVS2 + 1G >A, del5395
and 1100delC, which prevalance is 4.8%, 0.4%, 0.4% and
0.2%, respectively [6].
In this report we present the results of research on
association between congenital CHEK2 mutations and a
risk of BC in women originating from the North-Central
Poland, as well as the relation of these mutations to famil-
ial history of BC.
Materials and methods
Patients
420 women from the North-Central Poland (Kujawy-
Pomerania voivodeship) with consecutively diagnosed BC,
treated in 2007-2010 at the Oncology Center in Bydgoszcz,
were included in the investigation, regardless of histopato-
logical type and family history of the BC. The median age
at BC diagnosis in the whole group was 46 years (range
26-73). One woman was diagnosed with bilateral BC – two
primary cancers within two years (age 41 and 42).
In families of women with congenital CHEK2 mutations,
molecular tests were performed. 61% (255/420) of women
originated from families with at least one cancer in a close
relative, the most frequently cancer of breast, ovary, lung,
colon and prostate. 29% (121/420) of women originated
from families with history of BC in first- and/or second-
degree relatives. 5 out of 33 invited families (a total of 17
persons) agreed to be tested.
The first control group consisted of 435 healthy women
from the North-Central region of Poland. The data on
the general Polish population published by Cybulski et al.
(2006) were used as the second control group (by courtesy
of the Author) [6].
Informed consent was obtained from all patients and
healthy persons. The study was approved by the Ethics Com-
mittee of the Collegium Medicum, Nicolaus Copernicus
University in Bydgoszcz, Poland.
Molecular analysis
The CHEK2 mutations analysis was performed in all 420
patients and 17 members of their families, as well as in
all women from the first control group.
The mutations were investigated in DNA from periph-
eral blood leukocytes, extracted by standard salting-
out method. I157T and IVS2 + 1G > A were examined
by RFLP-PCR, 1100delC by ASO-PCR, and del5395 by
multiplex-PCR with two primer pairs flanking break-
point sites in introns 8 and 10 [3,6].
Statistical analysis included the comparison of the fre-
quency of variant alleles in studied and control groups.
Odds ratios (ORs) were calculated from two-by-two tables,
and statistical significance of differences between tested
and control groups was estimated using the Fisher’s
exact test.Results and discussion
At least one of CHEK2 mutations was found in 33 out
of 420 women diagnosed with BC (7.9%). This frequency
was higher than in both control groups, however differ-
ences were not statistically significant (first control group:
5.1%, p = 0.124; second control group: 5.8%, p = 0.109)
(Table 1). The observed lack of statistically significant cor-
relation between carrying of a congenital CHEK2mutation
and the risk of BC in the patients from North-Central
Poland may be caused by too small study groups.
The I157T, 1100delC and del5395 mutations separately
were disclosed with 6.0%, 0.5% and 0.5% frequency, re-
spectively, but none of these frequencies was statistically
significantly different from the frequency in both control
groups (first control group: 4.1%, 0.2%, 0.2%, respectively;
second control group: 4.8%, 0.2%, 0.4%, respectively).
However, the prevalence of IVS2 + 1G > A mutation
was three-fold higher in relation to the general Polish
population and the presence of this mutation turned out
to be associated with an increased risk of BC (1.2% vs.
0.4%; OR = 3.0; p = 0.039) (Table 1).
Reports of other authors show that the frequency of
CHEK2 mutations among women with diagnosed BC is
different in various regions of Poland. Among BC women
from throughout Poland and the South-Western Poland,
these mutations were detected with higher frequency than
in our investigations: 8.6% (385/4.454) and 9.9% (28/284),
respectively [7,8].
The increased risk of BC associated with three CHEK2
mutations IVS2 + 1G >A (1.1% vs. 0.48%; OR = 2.3, p =
0.04), 1100delC (0.5% vs. 0.25; OR = 2.0, p = 0.3) and I157T
(6.7 vs. 4.8%; OR = 1.4, p = 0.02) was showed in 2004 by
Cybulski et al. in BC women from the North-Western
Poland and with four CHEK2 mutations: IVS2 + 1G>A
(1.0% vs. 0.4%; OR = 2.4, p = 0.0008), 1100delC (0.4% vs.
0.2%; OR = 2.1, p = 0.07), I157T (6.5% vs. 4.8%; OR = 1.4,
p = 0.0004), del5395 (0.9% vs. 0.4%; OR = 2.0, p = 0.009) in
2007 by the same authors in a large group of BC women
from throughout the country [3,7].
On the contrary, Myszka et al. (2011) did not show
any relationship between the four investigated CHEK2
mutations and the risk of BC among BC women from
the South-Western Poland [8]. Such correlation was not
found either by Kwiatkowska et al. (2006), who investi-
gated only the 1100delC mutation in women with BC
originating from East-Central, West-Central and South-
Eastern Poland [9].
However, Han et al. (2013) in the meta-analysis of the
risk of breast cancer associated with CHEK2 I157T muta-
tion in 15.985 patients from four countries (Bogdanova
et al. 2005 [10]; Cybulski et al. 2004, 2009 [3,11]; Domagała
et al. 2012 [12]; Dufault et al. 2004 [13]; Irmejs et al. 2006
[14]; Kleibl et al. 2008 [15]; Serrano – Fernandez et al.
2009 [16]) found a strong correlation between carrying
Table 1 The correlation between a constitutional CHEK2 mutation and a risk of BC in analyzed women
CHEK2 mutations and
groups of tested women
Carriers/total n = 420 Controlsa n = 435 Controlsb n = 5.496
OR 95% CI p-Value OR 95% CI p-value
IVS2 + 1G > A
All women 5/420 (1.2%) 2.6 0.50-13.52 0.279 3.0 1.13-7.96 0.039c
Women from families with BC aggregation 1/121 (0.8%) 1.8 0.16-20.07 0.522 2.1 0.28-15.51 0.395
Controlsa 2/435 (0.5%) 1.0
Controlsb 22/5.496 (0.4%) 1.0
1100delC
All women 2/420 (0.5%) 2.1 0.19-22.99 0.618 2.2 0.49-9.80 0.262
Women from families with BC aggregation 2/121 (1.7%) 7.3 0.66-81.14 0.121 7.7 1.70-34.70 0.035c
Controlsa 1/435 (0.2%) 1.0
Controlsb 12/5.496 (0.2%) 1.0
del5395
All women 2/420 (0.5%) 2.1 0.19-22.99 0.618 1.1 0.26-4.63 0.707
Women from families with BC aggregation 1/121 (0.8%) 3.6 0.22-58.25 0.388 1.9 0.25-14.16 0.420
Controlsa 1/435 (0.2%) 1.0
Controlsb 24/5.496 (0.4%) 1.0
Any protein truncating mutation
All women 9/420 (2.1%) 2.4 0.72-7.72 0.169 2.1 1.01-4.17 0.053d
Women from families with BC aggregation 4/121 (3.3%) 3.7 0.91-14.95 0.072d 3.2 1.14-8.98 0.044c
Women with no family history of BC 5/299 (1.7%) 1.8 0.49-6.88 0.498 1.6 0.63-4.01 0.140
Controlsa 4/435 (0.9%) 1.0
Controlsb 58/5.496 (1.1%) 1.0
I157T
All women 25/420 (6.0%) 1.5 0.79-2.73 0.273 1.3 0.82-1.91 0.290
Women from families with BC aggregation 8/121 (6.6%) 1.6 0.70-3.87 0.327 1.4 0.68-2.90 0.286
Controlsa 18/435 (4.1%) 1.0
Controlsb 264/5.496 (4.8%) 1.0
Total CHEK2 mutation
All women 33*/420 (7.9%) 1.6 0.91-2.80 0.124 1.4 0.94-1.99 0.109
Women from families with BC aggregation 12/121 (9.9%) 2.1 0.99-4.31 0.055d 1.8 0.96-3.24 0.076d
Controlsa 22/435 (5.1%) 1.0
Controlsb 322/5.496 (5.8%) 1.0
*Two mutations (I157T, IVS + 1G > A) in one woman with BC.
aControls consisting of healthy women from North-Central region of Poland.
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p < 0.00001) [17].
In our study group any truncating CHEK2 mutation
occurred with two-fold higher frequency than in general
Polish population and we have also found their association
with the increased risk of BC (2.1% vs. 1.1%; OR = 2.1,
p = 0.053) (Table 1). Cybulski et al. also observed a strong
association of truncating mutations with elevated riskof BC in women from throughout the country (OR = 2.2;
p = 0.0001) [7].
We also investigated the association between a positive
familial history of BC in first- and/or second-degree rela-
tives and the risk of developing BC. In women from these
families we detected three-fold higher frequency of truncat-
ing CHEK2 mutations together than in the general Polish
population, and their association with the increased risk
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regard to our control group, differences were at the
limit of statistical significance (3.3% vs. 0.9%; OR = 3.7,
p = 0.072), only. Among patients with truncating CHEK2
mutations the risk of BC in the group of women from
families with BC aggregation was two-fold higher than
among women with no family history of BC (first con-
trol group: OR = 3.7 vs. OR = 1.8, second control group:
OR = 3.2 vs. OR = 1.6) (Table 1).
In women from families with BC aggregation, 1100delC
mutation frequency was eight and a half-fold higher in
relation to the general Polish population and the presence
of this individual mutation turned out to be associated
with an increased risk of BC (1.7% vs. 0.2%; OR = 7.7;
p = 0.035) (Table 1).
Cybulski et al. also showed a higher relative risk of BC
among women with family history of BC, carriers of one
of the three truncating mutations, from throughout the
Poland compared to women with no family history of BC:
4.1%, OR = 5.0 (95% CI, 3.3 to 7.6) versus 2.8%, OR = 3.3
(95% CI, 2.3 to 4.7) [18].
The results of family investigations indicate a strong,
statistically significant association of the truncating muta-Figure 1 Pedigrees of families A-E, with CHEK2 mutations. Black symbo
inside - healthy mutation carriers. Age of cancer or age of CHEK2 mutation
Lu - lung cancer; Li - liver cancer; Pr - prostate cancer; Co - colon cancer. A
carriers; N - analyzed persons who are not carriers of the mutation; n.t. - notions with BC development, which suggests that mutations
in CHEK2 gene are associated with BC risk, especially in
women originating from families with BC aggregation.
Our results are in favor of the results of Cybulski,
and in contradiction with the results of Myszka and
Kwiatkowska [3,7-9,18].
Our research, carried out in 5 families, confirmed heredi-
tary character of all detected CHEK2 mutations (Figure 1).
In family A, I157T mutation was detected in two sisters:
one with BC (age 51), and the second healthy (age at the
time of examination 46). In family B, woman with BC at
age 47 and her two healthy brothers (age 61 and 53), as well
as her two healthy daughters (age 26 and 22), were carriers
of I157T. Vertical transmission of I157T and IVS2 + 1G >A
mutations was also observed in family C. I157T was de-
tected in healthy mother (age 75) and two her daughters:
one healthy (age 50), one with BC (age 48). BC-affected
daughter inherited also second mutation, IVS2 + 1G >A,
through paternal line. The father, carrier of IVS2 + 1G >A,
was diagnosed with prostate cancer (age at diagnosis un-
known). Family D was burdened with the IVS2 + 1G >A
mutation, which was disclosed in mother (BC at age 57)
and in her two healthy daughters (age 38 and 25). 1100delCls - persons affected with cancer; white symbols with a black dot
diagnosis in healthy persons is given in brackets. Br - breast cancer;
rrows indicate probands. I157T, IVS2 + 1G > A or 1100delC - mutation
t tested.
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diagnosed with BC (age 51 and 43).
In conclusion, we found a strong association between
CHEK2 truncating mutations prevalence and breast can-
cer family history. We conclude that CHEK2 mutations
are rare in BC, but our results suggest a tumor suppressor
function of CHEK2 gene in a small proportion of breast
cancers. Furthermore, our results suggest that the CHEK2
mutations are low-penetrance alleles with respect to BC.
However, a variety of interactions between the mutated
CHEK2 with other genes can be related to the develop-
ment of BC. The presence of CHEK2 mutations in BC
highlights the importance of the integrity of the DNA
damage signals pathway in BC development. Although the
mechanisms by which CHEK2 mutations contribute to the
development of BC remain unknown, future studies may
confirm the observations shown in the present report.
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